Not Yet Recruiting
Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults - AI447-121
Uppdaterad:
23 augusti, 2018
|
ClinicalTrials.gov
Kön
Åldersintervall
Platser
Not Yet Recruiting
For more information regarding Bristol Myers Squibb (BMS) Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - at least 18 years of age with CHC, GT-1 - treatment-naïve and treatment-experienced (null or partial) responders - intolerant to interferon (IFN) - with or without cirrhosis Exclusion Criteria: - patients who received DCV and ASV as part of a clinical trial - patients who received DCV and ASV for any indication other than that which is locally approved - contraindications included in the approved Mexican prescribing information Other protocol defined inclusion/exclusion criteria could apply
Vi rekommenderar att du kontaktar BMS för att rapportera biverkningar.
Biverkningar (oönskade händelser) och andra rapporterbara händelser definieras här
För att rapportera biverkningar (oönskade händelser) eller reklamera ett läkemedel: Medicinsk information
466-SE-2100058